Analyzing Chugai Pharmaceutical (OTCMKTS:CHGCY) & Ascend Wellness (OTCMKTS:AAWH)

Chugai Pharmaceutical (OTCMKTS:CHGCY) and Ascend Wellness (OTCMKTS:AAWH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 17.3% of Ascend Wellness shares are held by institutional investors. 21.9% of Ascend Wellness shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Chugai Pharmaceutical and Ascend Wellness”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chugai Pharmaceutical	$8.41 billion	7.54	$2.91 billion	$0.92	20.96
Ascend Wellness	$500.58 million	0.20	-$118.19 million	($0.57)	-0.88

Chugai Pharmaceutical has higher revenue and earnings than Ascend Wellness. Ascend Wellness is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Chugai Pharmaceutical has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Ascend Wellness has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Profitability

This table compares Chugai Pharmaceutical and Ascend Wellness’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chugai Pharmaceutical	35.09%	23.76%	19.92%
Ascend Wellness	-23.31%	N/A	-10.85%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Chugai Pharmaceutical and Ascend Wellness, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chugai Pharmaceutical	0	3	1	1	2.60
Ascend Wellness	0	1	0	0	2.00

Summary

Chugai Pharmaceutical beats Ascend Wellness on 11 of the 14 factors compared between the two stocks.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Ascend Wellness

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.